Skip to main content

Table 2 Bivariate quantitative analyses of all investigated parameters in dependence of year of publication. All given data are calculated from the equations of the regression lines. For P-values see table 3

From: The fading of reported effectiveness. A meta-analysis of randomised controlled trials

  

Pravastatin

Atorvastatin

Timolol

Latanoprost

Reported effect size*

Change in 5 years

-3.22

+0.31

-0.56

-1.78

 

95% CI limits

(-4.50/-1.93)

(-3.29/+3.91)

(-0.79/-0.34)

(-3.04/-0.51)

Baseline†

Change in 5 years

-41.80

-14.63

-0.70

-1.82

 

95% CI limits

(-55.74/-27.86)

(-48.38/+19.11)

(-1.08/-0.32)

(-3.69/+0.05)

Study size‡

Change in 5 years

+533.54

+233.63

+80.55

-16.94

 

95% CI limits

(-3.94/+1071.01)

(-429.97/+897.23)

(+43.38/+117.71)

(-199.23/+165.35)

Treatment group§

Change in 5 years

-0.20

-0.28

-0.12

-0.23

 

95% CI limits

(-0.31/-0.08)

(-0.58/+0.01)

(-0.17/-0.06)

(-0.50/+0.03)

  1. Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.
  2. * Unit of measurement for reported effect size: Change of intraocular pressure measured in mmHg (Timolol, Latanoprost), change in low-density lipoprotein cholesterol measured in % (Pravastatin, Atorvastatin).
  3. † Unit of measurement for baseline: Intraocular pressure measured in mmHg (Timolol, Latanoprost), low-density lipoprotein cholesterol measured in mg/dl (Pravastatin, Atorvastatin). To convert low-density lipoprotein cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by 0.0259.
  4. ‡ Unit of measurement for study size: Number of patients included in final analysis.
  5. § The parameter treatment group has two possibilities: control group = 0, experimental group = 1. Point biserial correlation was used to obtain the equation of the regression line and to calculate the given data.